Form 4: Arcutis Biotherapeutics CEO Reallocates Significant Stock Holdings Through Gift Transfers

Arcutis Biotherapeutics President and CEO, Todd Franklin Watanabe, reported multiple gift-related transactions of common stock on June 10, 2025, reallocating shares from direct to indirect beneficial ownership via trusts.

Summary

• Todd Franklin Watanabe, President and Chief Executive Officer, and Director of Arcutis Biotherapeutics, Inc. (ARQT), filed a Form 4 reporting transactions that occurred on June 10, 2025.
• The filing indicates a re-allocation of 1,994 shares of common stock from his direct beneficial ownership to indirect beneficial ownership through two irrevocable trusts.
• Specifically, he disposed of two separate blocks of 997 shares each from his direct holdings via gift transactions (Code G) at a price of $0.00. Following these transactions, his direct beneficial ownership stands at 913,116 shares.
• Concurrently, 997 shares were acquired indirectly by The John Franklin Watanabe Irrevocable Trust, and another 997 shares were acquired indirectly by The Anderson Prest Watanabe Irrevocable Trust, both via gift transactions at $0.00. Each trust now holds 25,410 shares.
• The reporting person also maintains indirect beneficial ownership of 57,358 shares through Watanabe Ventures, LLC, and 124,956 shares through The Watanabe 2016 Irrevocable Trust.
• His direct beneficial ownership includes 1,315 shares purchased under the Arcutis Biotherapeutics, Inc. Employee Stock Purchase Plan on May 31, 2025.
• A Power of Attorney was granted to the company's Chief Financial Officer and General Counsel on June 10, 2025, to facilitate the preparation and filing of Section 16 reports on his behalf.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing (Form 4) reporting gift-related transfers, which are typically for estate planning purposes and do not inherently indicate positive or negative sentiment about the company's prospects. The CEO maintains significant total holdings.

Positives

• The transactions are gift-related, indicating personal estate planning rather than a sale for liquidity or a negative view of the company's prospects.
• The total number of shares beneficially owned by the CEO (directly and indirectly) remains unchanged, demonstrating continued alignment of interests with shareholders.
• The CEO continues to hold a significant number of shares, both directly (913,116 shares) and indirectly (totaling 207,724 shares across three trusts and an LLC), aligning his interests with shareholders.
• The inclusion of shares from the Employee Stock Purchase Plan indicates ongoing participation in company programs.

Negatives

• The direct beneficial ownership of the CEO decreased by 1,994 shares due to the gift transfers.

Future Outlook

This Form 4 filing pertains to insider stock transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide information relevant to broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• Todd Franklin Watanabe transferred 1,994 shares of common stock from his direct beneficial ownership to two irrevocable trusts, The John Franklin Watanabe Irrevocable Trust and The Anderson Prest Watanabe Irrevocable Trust, for which he serves as trustee.
• He also maintains indirect beneficial ownership through The Watanabe 2016 Irrevocable Trust, where his children are beneficiaries, and Watanabe Ventures, LLC, where he is Chief Operating Officer.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Trading, Beneficial Ownership, Stock Transaction, Gift, CEO, Director, Todd Franklin Watanabe, Equity, SEC Filing